Medicare may begin to cover renal denervation with Medtronic’s Symplicity device by October, which could drive coverage among ...

The stock's fall snapped a two-day winning streak.

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

Medtronic says CMS is opening a national coverage analysis on renal denervation (RDN) procedures for patients with ...

In the latest market close, Medtronic (MDT) reached $85.40, with a +0.18% movement compared to the previous day. The stock lagged the S&P 500's daily gain of 1.83%. Meanwhile, the Dow gained 1.65%, ...

Medtronic is picking up steam with recent product launches, and its balance sheet is a fortress. Read more about MDT stock ...

Medtronic Vietnam and the University Medical Center Ho Chi Minh City (UMC HCMC) have signed their fourth Memorandum of ...

For not just years but decades, Medtronic (NYSE: MDT) has proven to be a reliable dividend growth stock to own. The medical ...

While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now ...

Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price target of ...

Medtronic offers solid income potential with a 3.5% dividend yield. Read why MDT stock’s forward P/E ratio signals possible ...

New technologies for atrial fibrillation, hypertension, diabetes and neurological conditions are poised for fast growth, Martha said Monday at the J.P. Morgan Healthcare Conference.